"I wrote a treatment for a new trilogy that revolves around a “new” company, Biosyn Dodson’s company – the guy that bought off Nedry in film one had bought out Ingen and succeeded where they had failed by bringing the research to a whole new level combining nanotechnology and geneticengineering."